© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 10, 869-874,
May 19, 1999
© 1999 Oxford University Press
REPORTS |
Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis
Affiliations of authors: R. W. Stephens, I. J.Christensen, K. Danø, N. Brünner, The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark; H. J. Nielsen, Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen; O. Thorlacius-Ussing, Department of Surgical Gastroenterology, Aalborg Hospital, Denmark; S. Sørensen, Department of Clinical Biochemistry, Hvidovre Hospital, Copenhagen.
Correspondence to: Ross W. Stephens, Ph.D., The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark (e-mail: stephens.r{at}finsenlab.dk).
BACKGROUND: The proteolytic enzyme plasmin, which is generated from the precursor plasminogen by the action of urokinase plasminogen activator, is thought to play a role in tumor cell invasion and metastasis. Urokinase plasminogen activator receptor (uPAR) is functionally involved in the cell surface activation (i.e., cleavage) of plasminogen. Increased tumor tissue levels of uPAR are associated with poor prognosis in several types of cancer. This retrospective study was undertaken to test the relationship between preoperative plasma levels of soluble uPAR (suPAR) and survival in patients with colorectal cancer. METHODS: suPAR levels in preoperative plasma from 591 patients with colorectal cancer were determined by use of a kinetic enzyme-linked immunosorbent assay and analyzed with respect to associations with postoperative survival, Dukes' stage, age, and serum carcinoembryonic antigen level. Plasma suPAR measurements were log transformed for survival analysis, which employed the Kaplan-Meier method and the Cox proportional hazards model. All P values reported are two-sided. RESULTS: Univariate analysis, using the log-transformed suPAR concentrations, demonstrated that there was an increasing risk of mortality with increasing plasma suPAR level (P<.0001). An arbitrary cut point, the median for all patients (1.37 ng/mL), divided patients with Dukes' stage B, C, or D disease into statistically different prognostic groups. In multivariate Cox analysis including Dukes' stage, age, and carcinoembryonic antigen level, the suPAR concentration independently predicted survival (P<.0001). CONCLUSIONS: The preoperative plasma suPAR level independently predicted survival of patients with colorectal cancer. Further studies of plasma suPAR in patients with cancer are needed to evaluate the utility of plasma suPAR measurements and cut points in identifying high-risk patients among those with early stage disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Henic, C. Borgfeldt, I. J. Christensen, B. Casslen, and G. Hoyer-Hansen Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5785 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-B. Li, G. Niu, H. Wang, L. He, L. Yang, M. Ploug, and X. Chen Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET Clin. Cancer Res., August 1, 2008; 14(15): 4758 - 4766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Forsti, H. Lei, B. Tavelin, K. Enquist, R. Palmqvist, A. Altieri, G. Hallmans, K. Hemminki, and P. Lenner Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer Ann. Onc., December 1, 2007; 18(12): 1990 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lilja, A. Vickers, and P. Scardino Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer J. Clin. Oncol., February 1, 2007; 25(4): 347 - 348. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, C. G. Roehrborn, J. D. McConnell, S. Park, N. Alam, T. M. Wheeler, and K. M. Slawin Association of the Circulating Levels of the Urokinase System of Plasminogen Activation With the Presence of Prostate Cancer and Invasion, Progression, and Metastasis J. Clin. Oncol., February 1, 2007; 25(4): 349 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yang, H. Avila, H. Wang, J. Trevino, G. E. Gallick, Y. Kitadai, T. Sasaki, and D. D. Boyd Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression Cancer Res., August 15, 2006; 66(16): 7957 - 7967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gardsvoll, B. Gilquin, M. H. Le Du, A. Menez, T. J. D. Jorgensen, and M. Ploug Characterization of the Functional Epitope on the Urokinase Receptor: COMPLETE ALANINE SCANNING MUTAGENESIS SUPPLEMENTED BY CHEMICAL CROSS-LINKING J. Biol. Chem., July 14, 2006; 281(28): 19260 - 19272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Piironen, A. Haese, H. Huland, T. Steuber, I. J. Christensen, N. Brunner, K. Dano, G. Hoyer-Hansen, and H. Lilja Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum Clin. Chem., May 1, 2006; 52(5): 838 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Bauer, W. Liu, F. Fan, E. R. Camp, A. Yang, R. J. Somcio, C. D. Bucana, J. Callahan, G. C. Parry, D. B. Evans, et al. Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice Cancer Res., September 1, 2005; 65(17): 7775 - 7781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Selleri, N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization Blood, March 1, 2005; 105(5): 2198 - 2205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano, and G. Hoyer-Hansen Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor Clin. Chem., November 1, 2004; 50(11): 2059 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, L. Yang, Md. S. Jamaluddin, and D. D. Boyd The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells J. Biol. Chem., May 21, 2004; 279(21): 22674 - 22683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jo, K. S. Thomas, L. Wu, and S. L. Gonias Soluble Urokinase-type Plasminogen Activator Receptor Inhibits Cancer Cell Growth and Invasion by Direct Urokinase-independent Effects on Cell Signaling J. Biol. Chem., November 21, 2003; 278(47): 46692 - 46698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alfano, N. Sidenius, F. Blasi, and G. Poli The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection J. Leukoc. Biol., November 1, 2003; 74(5): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, J. Hicks, P. Khanbolooki, S.-J. Kim, C. Yan, Y. Wang, and D. Boyd Transgenic Mice Demonstrate Novel Promoter Regions for Tissue-Specific Expression of the Urokinase Receptor Gene Am. J. Pathol., August 1, 2003; 163(2): 453 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. May, R. Schmidt, S. M. Kanse, T. Chavakis, R. W. Stephens, A. Schomig, K. T. Preissner, and F.-J. Neumann Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction Blood, November 15, 2002; 100(10): 3611 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Memarzadeh, K. R. Kozak, L. Chang, S. Natarajan, P. Shintaku, S. T. Reddy, and R. Farias-Eisner Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer PNAS, August 6, 2002; 99(16): 10647 - 10652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alfano, N. Sidenius, B. Panzeri, F. Blasi, and G. Poli Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication PNAS, June 25, 2002; 99(13): 8862 - 8867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Riisbro, I. J. Christensen, T. Piironen, M. Greenall, B. Larsen, R. W. Stephens, C. Han, G. Hoyer-Hansen, K. Smith, N. Brunner, et al. Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1132 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Resnati, I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R PNAS, January 24, 2002; (2002) 22652999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Levitt, F. A. L. M. Eskens, K. J. O'Byrne, D. J. Propper, L. J. Denis, S. J. Owen, L. Choi, J. A. Foekens, S. Wilner, J. M. Wood, et al. Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer Clin. Cancer Res., July 1, 2001; 7(7): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bajou, V. Masson, R. D. Gerard, P. M. Schmitt, V. Albert, M. Praus, L. R. Lund, T. L. Frandsen, N. Brunner, K. Dano, et al. The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies J. Cell Biol., February 20, 2001; 152(4): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Denko and A. J. Giaccia Tumor Hypoxia, the Physiological Link between Trousseau's Syndrome (Carcinoma-induced Coagulopathy) and Metastasis Cancer Res., February 1, 2001; 61(3): 795 - 798. [Full Text]
|
|
|
|
|
|
N. Sidenius, C. F. M. Sier, H. Ullum, B. K. Pedersen, A. C. Lepri, F. Blasi, and J. Eugen-Olsen Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection Blood, December 15, 2000; 96(13): 4091 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Baker, F G Bergin, and D J Leaper Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression Mol. Pathol., December 1, 2000; 53(6): 307 - 312. [Abstract] [Full Text]
|
|
|
|
|
|
S. Mustjoki, N. Sidenius, C. F. M. Sier, F. Blasi, E. Elonen, R. Alitalo, and A. Vaheri Soluble Urokinase Receptor Levels Correlate with Number of Circulating Tumor Cells in Acute Myeloid Leukemia and Decrease Rapidly during Chemotherapy Cancer Res., December 1, 2000; 60(24): 7126 - 7132. [Abstract] [Full Text]
|
|
|
|
|
|
M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tatsumoto, E. Hiyama, Y. Murakami, Y. Imamura, J. W. Shay, Y. Matsuura, and T. Yokoyama High Telomerase Activity Is an Independent Prognostic Indicator of Poor Outcome in Colorectal Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2696 - 2701. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brünner, F. Jänicke, M. E. M.-v. Gelder, S. C. Henzen-Logmans, et al. The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients Cancer Res., February 1, 2000; 60(3): 636 - 643. [Abstract] [Full Text]
|
|
|
|
|
|
M. Resnati, I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R PNAS, February 5, 2002; 99(3): 1359 - 1364. [Abstract] [Full Text] [PDF]
|
|